Trial · NCT01722669
Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States
NCT01722669, Early phase 1, Completed, Beth Israel Deaconess Medical Center; results first posted 2020-10-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States. Trials, record NCT01722669. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01722669
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States
- NCT number
- NCT01722669
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 38 participants, actual
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Conditions
- Healthy
- Interventions
- isoquercetin or quercetin
- First posted
- 2012-11-07
- Last updated
- 2020-10-12
- Results first posted
- 2020-10-12
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | AUC | 24 hours | AUC 0-24 hours of measured plasma quercetin aglycone for Arms A1, B1, A2, B2, C Collected at timepoints: baseline and 1, 2, 4, 6, 8, and 24 hours after dose. PK and PDI samples were not measured for Arm D (anti-phospholipid antibody cohort) |
| Secondary | Reductase Activity of PDI Using Dieosin Glutathione Disulfide | 2 hours. Not measured in D | Measurement of protein disulfide inhibition in plasma using a fluorescent PDI substrate (dieosin glutathione disulfide) |
| Secondary | Platelet-induced Thrombin Generation (U/mL) | 4 hours | Thrombin induced thrombin generation measured in patient plasma |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | AUC | 24 hours | uM hr/L | MEAN | |
| SECONDARY | Reductase Activity of PDI Using Dieosin Glutathione Disulfide | 2 hours. Not measured in D | 2 hours after oral ingestion | Percent inhibition | MEAN |
| SECONDARY | Platelet-induced Thrombin Generation (U/mL) | 4 hours | 4 hours after single dose only measured in Arm C and Arm D | U/mL | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| AUC | Quercetin 500 mg (ARM A1) | 4.78 | Standard Deviation 1.67 | uM hr/L | |
| AUC | Isoquercetin 500 mg (ARM B1) | 15.00 | Standard Deviation 8.94 | uM hr/L | |
| AUC | Quercetin 500 mg + Ascorbic Acid (ARM A2) | 5.41 | Standard Deviation 2.13 | uM hr/L | |
| AUC | Isoquercetin 500 mg + Ascorbic Acid (ARM B2) | 16.34 | Standard Deviation 10.08 | uM hr/L | |
| AUC | Isoquercetin 1000 mg + Ascorbic Acid (ARM C) | 40.3 | Standard Deviation 17.11 | uM hr/L | |
| Reductase Activity of PDI Using Dieosin Glutathione Disulfide | Quercetin 500 mg (ARM A1) | 31.9 | Standard Deviation 24.14 | Percent inhibition | |
| Reductase Activity of PDI Using Dieosin Glutathione Disulfide | Isoquercetin 500 mg (ARM B1) | 63.2 | Standard Deviation 25.3 | Percent inhibition | |
| Reductase Activity of PDI Using Dieosin Glutathione Disulfide | Quercetin 500 mg + Ascorbic Acid (ARM A2) | 16 | Standard Deviation 31.8 | Percent inhibition | |
| Reductase Activity of PDI Using Dieosin Glutathione Disulfide | Isoquercetin 500 mg + Ascorbic Acid (ARM B2) | 8.3 | Standard Deviation 15.03 | Percent inhibition | |
| Reductase Activity of PDI Using Dieosin Glutathione Disulfide | Isoquercetin 1000 mg + Ascorbic Acid (ARM C) | 38 | Standard Deviation 35 | Percent inhibition |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Quercetin 500mg (ARM A1) | 5 | |
| Overall Study | STARTED | Isoquercetin 500mg (ARM B1) | 5 | |
| Overall Study | STARTED | Quercetin 500 mg + Ascorbic Acid (ARM A2) | 5 | |
| Overall Study | STARTED | Isoquercetin 500 mg + Ascorbic Acid (ARM B2) | 5 | |
| Overall Study | STARTED | Isoquercetin 1000 mg + Ascorbic Acid (ARM C) | 10 | |
| Overall Study | STARTED | Antiphospholipid Antibody Cohort (ARM D) | 8 | |
| Overall Study | COMPLETED | Quercetin 500mg (ARM A1) | 5 | |
| Overall Study | COMPLETED | Isoquercetin 500mg (ARM B1) | 5 | |
| Overall Study | COMPLETED | Quercetin 500 mg + Ascorbic Acid (ARM A2) | 5 | |
| Overall Study | COMPLETED | Isoquercetin 500 mg + Ascorbic Acid (ARM B2) | 5 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Quercetin 500 mg (ARM A1) | 0 | 5 |
| Total, all-cause mortality | Isoquercetin 500 mg (ARM B1) | 0 | 5 |
| Total, all-cause mortality | Quercetin 500 mg + Ascorbic Acid (ARM A2) | 0 | 5 |
| Total, all-cause mortality | Isoquercetin 500 mg + Ascorbic Acid (ARM B2) | 0 | 5 |
| Total, all-cause mortality | Isoquercetin 1000 mg + Ascorbic Acid (ARM C) | 0 | 10 |
| Total, all-cause mortality | Antiphospholipid Antibody (ARM D) | 0 | 6 |
| Total, other adverse events | Quercetin 500 mg (ARM A1) | 0 | 5 |
| Total, other adverse events | Isoquercetin 500 mg (ARM B1) | 0 | 5 |
| Total, other adverse events | Quercetin 500 mg + Ascorbic Acid (ARM A2) | 0 | 5 |
| Total, other adverse events | Isoquercetin 500 mg + Ascorbic Acid (ARM B2) | 0 | 5 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28097231 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01722669
GET https://conductscience.org/api/trials/v1/NCT01722669/registered